

Placebo and Nocebo Publications January 2021

1. Afach, S., Evrenoglou, T., Oubaya, N., Le Cleach, L., & Sbidian, E. (2021). Most randomized controlled trials for psoriasis used placebo comparators despite the availability of effective treatments. *J Clin Epidemiol*, 133, 72-79.
doi:10.1016/j.jclinepi.2021.01.013
<https://www.ncbi.nlm.nih.gov/pubmed/33482295>
2. Berger, S. E., Branco, P., Vachon-Preseu, E., Abdullah, T. B., Cecchi, G., & Apkarian, A. V. (2021). Quantitative language features identify placebo responders in chronic back pain. *Pain*. doi:10.1097/j.pain.0000000000002175
<https://www.ncbi.nlm.nih.gov/pubmed/33433145>
3. Case, L., Adler-Neal, A. L., Wells, R. E., & Zeidan, F. (2021). The role of expectations and endogenous opioids in mindfulness-based relief of experimentally-induced acute pain. *Psychosom Med*.
doi:10.1097/PSY.0000000000000908
<https://www.ncbi.nlm.nih.gov/pubmed/33480666>
4. De Smet, S., Nikolin, S., Moffa, A., Suen, P., Vanderhasselt, M. A., Brunoni, A. R., & Razza, L. B. (2021). Determinants of sham response in tDCS depression trials: a systematic review and meta-analysis. *Prog Neuropsychopharmacol Biol Psychiatry*, 109, 110261. doi:10.1016/j.pnpbp.2021.110261
<https://www.ncbi.nlm.nih.gov/pubmed/33497753>
5. Feldhaus, M. H., Horing, B., Sprenger, C., & Buchel, C. (2021). Association of nocebo hyperalgesia and basic somatosensory characteristics in a large cohort. *Sci Rep*, 11(1), 762. doi:10.1038/s41598-020-80386-y
<https://www.ncbi.nlm.nih.gov/pubmed/33436821>
6. Flowers, K. M., Patton, M. E., Hruschak, V. J., Fields, K. G., Schwartz, E., Zeballos, J., Kang, J. D., Edwards, R. R., Kaptchuk, T. J., & Schreiber, K. L. (2021). Conditioned open-label placebo for opioid reduction following spine surgery: a randomized, controlled trial. *Pain*.
doi:10.1097/j.pain.0000000000002185
<https://www.ncbi.nlm.nih.gov/pubmed/33449503>
7. Freed, B., Williams, B., Situ, X., Landsman, V., Kim, J., Moroz, A., Bang, H., & Park, J. J. (2021). Blinding, sham, and treatment effects in randomized controlled trials for back pain in 2000-2019: A review and meta-analytic approach. *Clin Trials*, 1740774520984870. doi:10.1177/1740774520984870
<https://www.ncbi.nlm.nih.gov/pubmed/33478258>

8. Geers, A. L., Faasse, K., Guevarra, D. A., Clemens, K. S., Helfer, S. G., & Colagiuri, B. (2021). Affect and emotions in placebo and nocebo effects: What do we know so far? *Social and Personality Psychology Compass*, 15(1), e12575. doi:<https://doi.org/10.1111/spc3.12575>
<https://onlinelibrary.wiley.com/doi/abs/10.1111/spc3.12575>
9. Gukasyan, N., & Nayak, S. M. (2021). Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy. *Transcult Psychiatry*. doi:10.1177/1363461520983684
<https://www.ncbi.nlm.nih.gov/pubmed/33499762>
10. Ikemoto, T., Ueno, T., Arai, Y. C., Wakao, N., Hirasawa, A., Hayashi, K., & Deie, M. (2020). Open-Label Placebo Trial among Japanese Patients with Chronic Low Back Pain. *Pain Res Manag*, 2020, 6636979. doi:10.1155/2020/6636979
<https://www.ncbi.nlm.nih.gov/pubmed/33425079>
11. Kaertner, L. S., Steinborn, M. B., Kettner, H., Spriggs, M. J., Roseman, L., Buchborn, T., Balaet, M., Timmermann, C., Erritzoe, D., & Carhart-Harris, R. L. (2021). Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. *Sci Rep*, 11(1), 1941. doi:10.1038/s41598-021-81446-7
<https://www.ncbi.nlm.nih.gov/pubmed/33479342>
12. Kiltz, U., Pudelko, J. C., Tsiami, S., Baraliakos, X., & Braun, J. (2021). Non-medical switching from reference to biosimilar etanercept - no evidence for nocebo effect: a retrospective analysis of real-life data. *Clin Exp Rheumatol*.
<https://www.ncbi.nlm.nih.gov/pubmed/33427615>
13. Kleine-Borgmann, J., Schmidt, K., Billinger, M., Forkmann, K., Wiech, K., & Bingel, U. (2021). Effects of open-label placebos on test performance and psychological well-being in healthy medical students: a randomized controlled trial. *Sci Rep*, 11(1), 2130. doi:10.1038/s41598-021-81502-2
<https://www.ncbi.nlm.nih.gov/pubmed/33483552>
14. Lee, I. S., Jung, W. M., Lee, Y. S., Wallraven, C., & Chae, Y. (2021). Operant and classical learning principles underlying mind-body interaction in pain modulation: a pilot fMRI study. *Sci Rep*, 11(1), 1663. doi:10.1038/s41598-021-81134-6
<https://www.ncbi.nlm.nih.gov/pubmed/33462278>

15. McLemore, B. H., McLemore, S. G., Rogers, R. R., Pederson, J. A., Williams, T. D., Marshall, M. R., & Ballmann, C. G. (2020). Nocebo Effects on Perceived Muscle Soreness and Exercise Performance Following Unaccustomed Resistance Exercise: A Pilot Study. *J Funct Morphol Kinesiol*, 5(2). doi:10.3390/jfmk5020040
<https://www.ncbi.nlm.nih.gov/pubmed/33467255>
16. Olson, J. A., & Raz, A. (2021). Applying insights from magic to improve deception in research: The Swiss cheese model. *Journal of Experimental Social Psychology*, 92, 104053. doi: 10.1016/j.jesp.2020.104053
<https://www.sciencedirect.com/science/article/pii/S0022103120303930>
17. Peerdeman, K. J., Geers, A. L., Della Porta, D., Veldhuijzen, D. S., & Kirsch, I. (2021). Underpredicting pain: an experimental investigation into the benefits and risks. *Pain*. doi:10.1097/j.pain.0000000000002199
<https://www.ncbi.nlm.nih.gov/pubmed/33470747>
18. Perfitt, J. S., Plunkett, N., & Jones, S. (2020). Placebo effect in the management of chronic pain. *BJA Educ*, 20(11), 382-387. doi:10.1016/j.bjae.2020.07.002
<https://www.ncbi.nlm.nih.gov/pubmed/33456922>
19. Petit, J., Antignac, M., Poilverd, R. M., Baratto, R., Darthout, S., Desouches, S., Louati, K., Deparis, N., Berenbaum, F., & Beauvais, C. (2021). Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar. *RMD Open*, 7(1). doi:10.1136/rmdopen-2020-001396
<https://www.ncbi.nlm.nih.gov/pubmed/33495387>
20. Richardson, M., Kleinstauber, M., & Wong, D. (2020). Nocebo-Hypothesis Cognitive Behavioral Therapy (NH-CBT) for Persons With Functional Neurological Symptoms (Motor Type): Design and Implementation of a Randomized Active-Controlled Trial. *Front Neurol*, 11, 586359. doi:10.3389/fneur.2020.586359
<https://www.ncbi.nlm.nih.gov/pubmed/33424742>
21. Rutgen, M., Wirth, E. M., Riecanaky, I., Hummer, A., Windischberger, C., Petrovic, P., Silani, G., & Lamm, C. (2021). Beyond Sharing Unpleasant Affect-Evidence for Pain-Specific Opioidergic Modulation of Empathy for Pain. *Cereb Cortex*. doi:10.1093/cercor/bhaa385
<https://www.ncbi.nlm.nih.gov/pubmed/33454739>

22. Schlintl, C., & Schienle, A. (2020). Information About the Optimism of a Placebo/Nocebo Provider and Placebo/Nocebo Side Effects. *Front Psychol*, 11, 608595. doi:10.3389/fpsyg.2020.608595
<https://www.ncbi.nlm.nih.gov/pubmed/33519617>
23. Slomski, A. (2021). "Important Conversations" Are Needed to Explain the Nocebo Effect. *JAMA*. doi:10.1001/jama.2020.25840
<https://www.ncbi.nlm.nih.gov/pubmed/33533926>
24. Yang, Z., Li, Y., Zou, Z., Zhao, Y., Zhang, W., Jiang, H., Hou, Y., Li, Y., & Zheng, Q. (2021). Does patient's expectation benefit acupuncture treatment?: A protocol for systematic review and meta-analysis. *Medicine*, 100(1), e24178. doi:10.1097/MD.00000000000024178
<https://www.ncbi.nlm.nih.gov/pubmed/33429804>
25. Zareba, R., Rysiak, E., Przyłipiak, A., & Oscilowska, I. (2021). Ethical - legal evaluation of the use of placebo in clinical trials. *J Cosmet Dermatol*. doi:10.1111/jocd.13967
<https://www.ncbi.nlm.nih.gov/pubmed/33533184>